IL6 and major depressive disorder: Indeed, treatment with an IL‐6 monoclonal antibody was shown to be effective in promoting resilience in mice, raising the hypothesis that reducing peripheral pro‐inflammatory cytokine levels could help achieve remission of depressive symptoms in humans, at least in subpopulations of MDD patients characterized by exacerbated immune response (Hodes et al., 2014).